Choosing the appropriate pharmacotherapy for nonspecific chronic low back pain.


Journal

Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112

Informations de publication

Date de publication:
21 Dec 2022
Historique:
received: 06 10 2022
accepted: 29 11 2022
entrez: 21 12 2022
pubmed: 22 12 2022
medline: 24 12 2022
Statut: epublish

Résumé

The pharmacological management of nonspecific chronic low back pain (NCLBP) aims to restore daily activities and improve the quality of life. No magic bullet exists for NCLBP; interventions to reduce pain and disability are available, but long-term results are unpredictable. Education in this regard needs to improve. This is often hard to accept for clinicians and patients, and provides a fertile soil to quacks, faith healers, and gurus to promote miraculous non-evidence-based solutions. The management of NCLBP is not well codified and extremely heterogeneous, and residual symptoms are common. Depending on the individual severity of NCLPB, pharmacological management may range from nonopioid to opioid analgesics. It is important to identify patients with generalized sensory hypersensitivity, who may benefit from a dedicated therapy. In this editorial, we provide an evidenced-based overview of the principles of pharmacological management of NCLPB.

Identifiants

pubmed: 36544200
doi: 10.1186/s13018-022-03426-5
pii: 10.1186/s13018-022-03426-5
pmc: PMC9773490
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

556

Informations de copyright

© 2022. The Author(s).

Références

JAMA. 2018 Mar 6;319(9):872-882
pubmed: 29509867
Expert Rev Clin Pharmacol. 2021 May;14(5):635-641
pubmed: 33706636
Expert Opin Pharmacother. 2021 Jan;22(1):109-119
pubmed: 32885995
CMAJ. 2018 Jul 3;190(26):E786-E793
pubmed: 29970367
Br Med Bull. 2021 Jun 10;138(1):85-95
pubmed: 33884409
J Orthop. 2017 Jun 29;14(3):410-415
pubmed: 28736490
Pain. 2016 Jul;157(7):1499-1507
pubmed: 26963844
JAMA Neurol. 2019 Jan 1;76(1):28-34
pubmed: 30326006
Pain Res Manag. 2019 Feb 4;2019:4905013
pubmed: 30863474
Spine (Phila Pa 1976). 2016 Nov 15;41(22):1709-1717
pubmed: 27831985
Fukushima J Med Sci. 2017 Apr 28;63(1):8-15
pubmed: 28331155
Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85
pubmed: 20461028
Eur Spine J. 2018 Jan;27(1):60-75
pubmed: 28429142

Auteurs

Filippo Migliorini (F)

Department of Orthopedic, Trauma, and Reconstructive Surgery, University Clinic Aachen, RWTH Aachen University Clinic, 52064, Aachen, Germany. migliorini.md@gmail.com.
Department of Orthopaedic and Trauma Surgery, Eifelklinik St.Brigida, 52152, Simmerath, Germany. migliorini.md@gmail.com.

Nicola Maffulli (N)

Department of Medicine, Surgery and Dentistry, University of Salerno, 84081, Baronissi, SA, Italy.
Queen Mary University of London, Barts and the London School of Medicine and Dentistry, Mile End Hospital, London, E1 4DG, England.
School of Pharmacy and Bioengineering, Keele University Faculty of Medicine, Stoke On Trent, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH